In this multicenter double-blind randomized study the analgesic efficacy and safety of 50 mg tramadol was compared against 50 mg pentazocine by mouth in the treatment of 160 patients with acute pain following prolapsed intervertebral disc repair. The day of surgery patients were treated with parenteral opioids. The study started the morning after surgery. A wash out period of four hours was allowed after parenteral analgesics. Pain assessment was made using a visual analogue scale (VAS) and a verbal rating scale (VRS) during a six hours observation period. Remedication with the same drug at the same dosage was allowed if pain relief was unsatisfactory. Overall analgesic activity and spontaneously reported side effects were also registered. Results showed both treatments provided equivalent effective analgesia for the six hours observation period. The global assessment of analgesia by patient and observer was not significantly different for both treatments, although less additional medication was required in the pentazocine group. Side effects were quite common in both groups, and occurred more frequently in the pentazocine group.
Download full-text PDF |
Source |
---|
J Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFQuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed in first complete remission (CR1) or composite CR1 (CRc1) on overall survival (OS), considering treatment randomization. Post-hoc extended Cox regression multivariable analyses were conducted in patients who achieved CR/CRc by the end of induction, including allo-HCT in CR1/CRc1 as a time-dependent variable to identify prognostic and predictive factors for OS.
View Article and Find Full Text PDFFront Immunol
March 2025
State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
This study evaluated the efficacy and safety of camrelizumab combined with platinum-based chemotherapy (taxanes [T] or fluorouracil agents [F] plus platinum [P] drugs) as the first-line treatment in advanced esophageal squamous cell carcinoma (ESCC), using immune repertoire sequencing (IRS) to explore treatment response mechanism. In this multi-center, prospective cohort study, 88 patients received camrelizumab plus TP or FP, achieving a 1-year progression-free survival of 56.8% and overall survival of 68.
View Article and Find Full Text PDFCureus
March 2025
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, JPN.
Background And Objective: For treating community-acquired pneumonia (CAP) in adults, early switching from injectable to oral antimicrobials (switch therapy) is accepted once the clinical course is favorable. Lascufloxacin (LSFX) is a quinolone antibacterial agent, available in intravenous and oral formulations, demonstrating antibacterial activity against a relatively broad spectrum of community-onset pneumonia (COP). No switch therapy using the same drug from injectable to oral antimicrobials has been reported; therefore, we conducted the study to confirm the efficacy and safety of the switch therapy using LSFX.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!